BE5 Stock Overview

A clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. More details

BE5 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap (€1M)

+ 3 more risks

CNS Pharmaceuticals, Inc. Competitors

TFF Pharmaceuticals

MUN:0K30

€9.7m

Biofrontera

XTRA:B8FK

€15.2m

SynBiotic

DUSE:SBX

€26.5m

Cantourage Group

XTRA:HIGH

€57.6m

Price History & Performance

Summary of share price highs, lows and changes for CNS Pharmaceuticals
Historical stock prices
Current Share Price	US$1.30
52 Week High	US$3.53
52 Week Low	US$1.12
Beta	1.12
1 Month Change	-41.45%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-50.97%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	BE5	DE Pharmaceuticals	DE Market
7D	-61.0%	-2.5%	-2.1%
1Y	n/a	-19.7%	9.1%

Return vs Industry: Insufficient data to determine how BE5 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how BE5 performed against the German Market.

Price Volatility

Is BE5's price volatile compared to industry and market?
BE5 volatility
BE5 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	4.2%
Market Average Movement	5.5%
10% most volatile stocks in DE Market	11.9%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: BE5's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine BE5's volatility change over the past year.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

About the Company

Founded	Employees	CEO	Website
2017	4	John Climaco	www.cnspharma.com

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNS Pharmaceuticals, Inc. Fundamentals Summary

How do CNS Pharmaceuticals's earnings and revenue compare to its market cap?
BE5 fundamental statistics
Market cap	€1.38m
Earnings (TTM)	-€15.76m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is BE5 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BE5 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$17.06m
Earnings	-US$17.06m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-14.84
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.9%

How did BE5 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/29 09:39
End of Day Share Price	2025/03/28 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CNS Pharmaceuticals, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Matthew Cross	Alliance Global Partners
Bruce Jackson	Benchmark Company